Numinus Wellness Inc.
Numinus Wellness Inc. (NUMIF) Stock Competitors & Peer Comparison
See (NUMIF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUMIF | $0.01 | +1.11% | 2.9M | -0.30 | -$0.03 | N/A |
| FSNUY | $12.78 | +1.67% | 114.7B | 16.11 | $0.79 | +2.22% |
| FSNUF | $57.00 | +4.88% | 32.1B | 18.10 | $3.15 | +1.99% |
| JDHIY | $7.00 | +2.19% | 22.4B | 29.17 | $0.24 | N/A |
| JDHIF | $6.15 | +0.00% | 19.7B | 29.29 | $0.21 | N/A |
| FMCQF | $44.25 | -10.08% | 12.4B | 15.26 | $2.90 | +3.67% |
| BDULF | $0.66 | +0.00% | 10.5B | 22.00 | $0.03 | +4.59% |
| BDUUY | $25.24 | +23.60% | 10B | 20.69 | $1.22 | +3.75% |
| IHHHF | $1.10 | -24.14% | 9.7B | 15.71 | $0.07 | +2.33% |
| BDUUF | $0.60 | -7.69% | 9.5B | 20.00 | $0.03 | +5.05% |
Stock Comparison
NUMIF vs FSNUY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, FSNUY has a market cap of 114.7B. Regarding current trading prices, NUMIF is priced at $0.01, while FSNUY trades at $12.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas FSNUY's P/E ratio is 16.11. In terms of profitability, NUMIF's ROE is +11.51%, compared to FSNUY's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to FSNUY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FSNUY's competition here
NUMIF vs FSNUF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, FSNUF has a market cap of 32.1B. Regarding current trading prices, NUMIF is priced at $0.01, while FSNUF trades at $57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas FSNUF's P/E ratio is 18.10. In terms of profitability, NUMIF's ROE is +11.51%, compared to FSNUF's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to FSNUF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FSNUF's competition here
NUMIF vs JDHIY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, JDHIY has a market cap of 22.4B. Regarding current trading prices, NUMIF is priced at $0.01, while JDHIY trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas JDHIY's P/E ratio is 29.17. In terms of profitability, NUMIF's ROE is +11.51%, compared to JDHIY's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to JDHIY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JDHIY's competition here
NUMIF vs JDHIF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, JDHIF has a market cap of 19.7B. Regarding current trading prices, NUMIF is priced at $0.01, while JDHIF trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas JDHIF's P/E ratio is 29.29. In terms of profitability, NUMIF's ROE is +11.51%, compared to JDHIF's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to JDHIF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JDHIF's competition here
NUMIF vs FMCQF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, FMCQF has a market cap of 12.4B. Regarding current trading prices, NUMIF is priced at $0.01, while FMCQF trades at $44.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas FMCQF's P/E ratio is 15.26. In terms of profitability, NUMIF's ROE is +11.51%, compared to FMCQF's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to FMCQF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FMCQF's competition here
NUMIF vs BDULF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BDULF has a market cap of 10.5B. Regarding current trading prices, NUMIF is priced at $0.01, while BDULF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BDULF's P/E ratio is 22.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to BDULF's ROE of +0.15%. Regarding short-term risk, NUMIF is more volatile compared to BDULF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDULF's competition here
NUMIF vs BDUUY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BDUUY has a market cap of 10B. Regarding current trading prices, NUMIF is priced at $0.01, while BDUUY trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BDUUY's P/E ratio is 20.69. In terms of profitability, NUMIF's ROE is +11.51%, compared to BDUUY's ROE of +0.15%. Regarding short-term risk, NUMIF is more volatile compared to BDUUY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDUUY's competition here
NUMIF vs IHHHF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, IHHHF has a market cap of 9.7B. Regarding current trading prices, NUMIF is priced at $0.01, while IHHHF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas IHHHF's P/E ratio is 15.71. In terms of profitability, NUMIF's ROE is +11.51%, compared to IHHHF's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to IHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check IHHHF's competition here
NUMIF vs BDUUF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BDUUF has a market cap of 9.5B. Regarding current trading prices, NUMIF is priced at $0.01, while BDUUF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BDUUF's P/E ratio is 20.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to BDUUF's ROE of +0.15%. Regarding short-term risk, NUMIF is more volatile compared to BDUUF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BDUUF's competition here
NUMIF vs RMYHY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RMYHY has a market cap of 6B. Regarding current trading prices, NUMIF is priced at $0.01, while RMYHY trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RMYHY's P/E ratio is 29.77. In terms of profitability, NUMIF's ROE is +11.51%, compared to RMYHY's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to RMYHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RMYHY's competition here
NUMIF vs RMSYF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RMSYF has a market cap of 5.7B. Regarding current trading prices, NUMIF is priced at $0.01, while RMSYF trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RMSYF's P/E ratio is 357.14. In terms of profitability, NUMIF's ROE is +11.51%, compared to RMSYF's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to RMSYF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RMSYF's competition here
NUMIF vs BUHPF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BUHPF has a market cap of 4.5B. Regarding current trading prices, NUMIF is priced at $0.01, while BUHPF trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BUHPF's P/E ratio is 20.93. In terms of profitability, NUMIF's ROE is +11.51%, compared to BUHPF's ROE of +0.26%. Regarding short-term risk, NUMIF is more volatile compared to BUHPF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BUHPF's competition here
NUMIF vs ANHGY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, NUMIF is priced at $0.01, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, NUMIF's ROE is +11.51%, compared to ANHGY's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ANHGY's competition here
NUMIF vs BUGDF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BUGDF has a market cap of 3.8B. Regarding current trading prices, NUMIF is priced at $0.01, while BUGDF trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BUGDF's P/E ratio is 16.96. In terms of profitability, NUMIF's ROE is +11.51%, compared to BUGDF's ROE of +0.26%. Regarding short-term risk, NUMIF is more volatile compared to BUGDF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BUGDF's competition here
NUMIF vs MCVEY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MCVEY has a market cap of 3.2B. Regarding current trading prices, NUMIF is priced at $0.01, while MCVEY trades at $21.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MCVEY's P/E ratio is 52.54. In terms of profitability, NUMIF's ROE is +11.51%, compared to MCVEY's ROE of +0.14%. Regarding short-term risk, NUMIF is more volatile compared to MCVEY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCVEY's competition here
NUMIF vs RHCGF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RHCGF has a market cap of 3.2B. Regarding current trading prices, NUMIF is priced at $0.01, while RHCGF trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RHCGF's P/E ratio is -11.11. In terms of profitability, NUMIF's ROE is +11.51%, compared to RHCGF's ROE of -0.14%. Regarding short-term risk, NUMIF is more volatile compared to RHCGF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RHCGF's competition here
NUMIF vs MCVEF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MCVEF has a market cap of 2.7B. Regarding current trading prices, NUMIF is priced at $0.01, while MCVEF trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MCVEF's P/E ratio is 34.62. In terms of profitability, NUMIF's ROE is +11.51%, compared to MCVEF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to MCVEF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCVEF's competition here
NUMIF vs JXFGF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, JXFGF has a market cap of 2.7B. Regarding current trading prices, NUMIF is priced at $0.01, while JXFGF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas JXFGF's P/E ratio is -20.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to JXFGF's ROE of -0.11%. Regarding short-term risk, NUMIF is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check JXFGF's competition here
NUMIF vs EXETF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, EXETF has a market cap of 1.8B. Regarding current trading prices, NUMIF is priced at $0.01, while EXETF trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas EXETF's P/E ratio is 23.22. In terms of profitability, NUMIF's ROE is +11.51%, compared to EXETF's ROE of +0.48%. Regarding short-term risk, NUMIF is more volatile compared to EXETF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check EXETF's competition here
NUMIF vs LWSCF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, LWSCF has a market cap of 1.6B. Regarding current trading prices, NUMIF is priced at $0.01, while LWSCF trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas LWSCF's P/E ratio is 44.91. In terms of profitability, NUMIF's ROE is +11.51%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to LWSCF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check LWSCF's competition here
NUMIF vs RAFLF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, NUMIF is priced at $0.01, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RAFLF's P/E ratio is 26.50. In terms of profitability, NUMIF's ROE is +11.51%, compared to RAFLF's ROE of +0.06%. Regarding short-term risk, NUMIF is more volatile compared to RAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RAFLF's competition here
NUMIF vs TTALF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, TTALF has a market cap of 1.4B. Regarding current trading prices, NUMIF is priced at $0.01, while TTALF trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas TTALF's P/E ratio is 13.10. In terms of profitability, NUMIF's ROE is +11.51%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to TTALF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check TTALF's competition here
NUMIF vs RKAGY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RKAGY has a market cap of 1.1B. Regarding current trading prices, NUMIF is priced at $0.01, while RKAGY trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RKAGY's P/E ratio is 24.73. In terms of profitability, NUMIF's ROE is +11.51%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, NUMIF is more volatile compared to RKAGY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RKAGY's competition here
NUMIF vs RYHTY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RYHTY has a market cap of 1.1B. Regarding current trading prices, NUMIF is priced at $0.01, while RYHTY trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RYHTY's P/E ratio is -4.59. In terms of profitability, NUMIF's ROE is +11.51%, compared to RYHTY's ROE of -0.14%. Regarding short-term risk, NUMIF is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RYHTY's competition here
NUMIF vs LTGHF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, LTGHF has a market cap of 1B. Regarding current trading prices, NUMIF is priced at $0.01, while LTGHF trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas LTGHF's P/E ratio is -12.02. In terms of profitability, NUMIF's ROE is +11.51%, compared to LTGHF's ROE of +8.48%. Regarding short-term risk, NUMIF is more volatile compared to LTGHF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check LTGHF's competition here
NUMIF vs RHKJF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, NUMIF is priced at $0.01, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, NUMIF's ROE is +11.51%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, NUMIF is more volatile compared to RHKJF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RHKJF's competition here
NUMIF vs LTGHY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, LTGHY has a market cap of 948.1M. Regarding current trading prices, NUMIF is priced at $0.01, while LTGHY trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas LTGHY's P/E ratio is -10.40. In terms of profitability, NUMIF's ROE is +11.51%, compared to LTGHY's ROE of +0.38%. Regarding short-term risk, NUMIF is more volatile compared to LTGHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check LTGHY's competition here
NUMIF vs NWKHY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NWKHY has a market cap of 854.5M. Regarding current trading prices, NUMIF is priced at $0.01, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NWKHY's P/E ratio is 10.39. In terms of profitability, NUMIF's ROE is +11.51%, compared to NWKHY's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to NWKHY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NWKHY's competition here
NUMIF vs KDGTF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, NUMIF is priced at $0.01, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, NUMIF's ROE is +11.51%, compared to KDGTF's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check KDGTF's competition here
NUMIF vs WHTCF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, WHTCF has a market cap of 667M. Regarding current trading prices, NUMIF is priced at $0.01, while WHTCF trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas WHTCF's P/E ratio is -130.55. In terms of profitability, NUMIF's ROE is +11.51%, compared to WHTCF's ROE of -0.06%. Regarding short-term risk, NUMIF is more volatile compared to WHTCF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check WHTCF's competition here
NUMIF vs WFHG Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, WFHG has a market cap of 472.5M. Regarding current trading prices, NUMIF is priced at $0.01, while WFHG trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas WFHG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to WFHG's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to WFHG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check WFHG's competition here
NUMIF vs ORRRY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, NUMIF is priced at $0.01, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, NUMIF's ROE is +11.51%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, NUMIF is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ORRRY's competition here
NUMIF vs BTMDW Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, NUMIF is priced at $0.01, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, NUMIF's ROE is +11.51%, compared to BTMDW's ROE of -0.35%. Regarding short-term risk, NUMIF is more volatile compared to BTMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BTMDW's competition here
NUMIF vs ORPEF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ORPEF has a market cap of 241.9M. Regarding current trading prices, NUMIF is priced at $0.01, while ORPEF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ORPEF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to ORPEF's ROE of -0.13%. Regarding short-term risk, NUMIF is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ORPEF's competition here
NUMIF vs MFCSF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MFCSF has a market cap of 219.1M. Regarding current trading prices, NUMIF is priced at $0.01, while MFCSF trades at $11.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MFCSF's P/E ratio is 15.06. In terms of profitability, NUMIF's ROE is +11.51%, compared to MFCSF's ROE of +0.27%. Regarding short-term risk, NUMIF is more volatile compared to MFCSF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MFCSF's competition here
NUMIF vs MKLNF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MKLNF has a market cap of 214.8M. Regarding current trading prices, NUMIF is priced at $0.01, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, NUMIF's ROE is +11.51%, compared to MKLNF's ROE of +0.16%. Regarding short-term risk, NUMIF is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MKLNF's competition here
NUMIF vs CHHHF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, CHHHF has a market cap of 165.6M. Regarding current trading prices, NUMIF is priced at $0.01, while CHHHF trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas CHHHF's P/E ratio is 8.80. In terms of profitability, NUMIF's ROE is +11.51%, compared to CHHHF's ROE of +0.28%. Regarding short-term risk, NUMIF is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CHHHF's competition here
NUMIF vs HWAIF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, HWAIF has a market cap of 155M. Regarding current trading prices, NUMIF is priced at $0.01, while HWAIF trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas HWAIF's P/E ratio is -4.80. In terms of profitability, NUMIF's ROE is +11.51%, compared to HWAIF's ROE of -0.39%. Regarding short-term risk, NUMIF is more volatile compared to HWAIF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HWAIF's competition here
NUMIF vs COLRF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, NUMIF is priced at $0.01, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas COLRF's P/E ratio is -8.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to COLRF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check COLRF's competition here
NUMIF vs VTIAF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, VTIAF has a market cap of 108.9M. Regarding current trading prices, NUMIF is priced at $0.01, while VTIAF trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas VTIAF's P/E ratio is -8.93. In terms of profitability, NUMIF's ROE is +11.51%, compared to VTIAF's ROE of -0.71%. Regarding short-term risk, NUMIF is more volatile compared to VTIAF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check VTIAF's competition here
NUMIF vs TOKIF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, TOKIF has a market cap of 101.4M. Regarding current trading prices, NUMIF is priced at $0.01, while TOKIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas TOKIF's P/E ratio is -0.57. In terms of profitability, NUMIF's ROE is +11.51%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, NUMIF is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check TOKIF's competition here
NUMIF vs NAFS Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NAFS has a market cap of 59.6M. Regarding current trading prices, NUMIF is priced at $0.01, while NAFS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NAFS's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to NAFS's ROE of +0.31%. Regarding short-term risk, NUMIF is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NAFS's competition here
NUMIF vs MCIOF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, NUMIF is priced at $0.01, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, NUMIF's ROE is +11.51%, compared to MCIOF's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MCIOF's competition here
NUMIF vs ASSF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, NUMIF is priced at $0.01, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ASSF's P/E ratio is -33.33. In terms of profitability, NUMIF's ROE is +11.51%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, NUMIF is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ASSF's competition here
NUMIF vs NVLPF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NVLPF has a market cap of 26.2M. Regarding current trading prices, NUMIF is priced at $0.01, while NVLPF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NVLPF's P/E ratio is 30.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to NVLPF's ROE of -0.01%. Regarding short-term risk, NUMIF is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NVLPF's competition here
NUMIF vs USNU Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, NUMIF is priced at $0.01, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas USNU's P/E ratio is -9.41. In terms of profitability, NUMIF's ROE is +11.51%, compared to USNU's ROE of -0.71%. Regarding short-term risk, NUMIF is more volatile compared to USNU. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check USNU's competition here
NUMIF vs HQDA Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, NUMIF is priced at $0.01, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas HQDA's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to HQDA's ROE of -0.06%. Regarding short-term risk, NUMIF is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HQDA's competition here
NUMIF vs GBCS Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, GBCS has a market cap of 12.6M. Regarding current trading prices, NUMIF is priced at $0.01, while GBCS trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas GBCS's P/E ratio is -14.64. In terms of profitability, NUMIF's ROE is +11.51%, compared to GBCS's ROE of +0.13%. Regarding short-term risk, NUMIF is more volatile compared to GBCS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GBCS's competition here
NUMIF vs EVGRF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, EVGRF has a market cap of 11.9M. Regarding current trading prices, NUMIF is priced at $0.01, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas EVGRF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to EVGRF's ROE of +0.22%. Regarding short-term risk, NUMIF is more volatile compared to EVGRF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check EVGRF's competition here
NUMIF vs FPCG Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, NUMIF is priced at $0.01, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas FPCG's P/E ratio is 0.09. In terms of profitability, NUMIF's ROE is +11.51%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FPCG's competition here
NUMIF vs HLYK Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, HLYK has a market cap of 9.4M. Regarding current trading prices, NUMIF is priced at $0.01, while HLYK trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas HLYK's P/E ratio is -2.75. In terms of profitability, NUMIF's ROE is +11.51%, compared to HLYK's ROE of +0.88%. Regarding short-term risk, NUMIF is more volatile compared to HLYK. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HLYK's competition here
NUMIF vs BICX Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BICX has a market cap of 7.6M. Regarding current trading prices, NUMIF is priced at $0.01, while BICX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BICX's P/E ratio is -1.25. In terms of profitability, NUMIF's ROE is +11.51%, compared to BICX's ROE of +0.41%. Regarding short-term risk, NUMIF is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BICX's competition here
NUMIF vs RVLWF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RVLWF has a market cap of 5.4M. Regarding current trading prices, NUMIF is priced at $0.01, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, NUMIF's ROE is +11.51%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, NUMIF is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RVLWF's competition here
NUMIF vs VLXC Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, VLXC has a market cap of 3.9M. Regarding current trading prices, NUMIF is priced at $0.01, while VLXC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas VLXC's P/E ratio is -4.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to VLXC's ROE of +0.74%. Regarding short-term risk, NUMIF is more volatile compared to VLXC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check VLXC's competition here
NUMIF vs XCRT Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, XCRT has a market cap of 3.5M. Regarding current trading prices, NUMIF is priced at $0.01, while XCRT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas XCRT's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to XCRT's ROE of +0.26%. Regarding short-term risk, NUMIF is more volatile compared to XCRT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check XCRT's competition here
NUMIF vs RHEP Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, RHEP has a market cap of 3.1M. Regarding current trading prices, NUMIF is priced at $0.01, while RHEP trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas RHEP's P/E ratio is -7.94. In terms of profitability, NUMIF's ROE is +11.51%, compared to RHEP's ROE of -0.04%. Regarding short-term risk, NUMIF is more volatile compared to RHEP. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check RHEP's competition here
NUMIF vs EPWCF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, NUMIF is priced at $0.01, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, NUMIF is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check EPWCF's competition here
NUMIF vs NRPR Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NRPR has a market cap of 2.1M. Regarding current trading prices, NUMIF is priced at $0.01, while NRPR trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NRPR's P/E ratio is -0.03. In terms of profitability, NUMIF's ROE is +11.51%, compared to NRPR's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to NRPR. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NRPR's competition here
NUMIF vs KJFI Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, KJFI has a market cap of 1.6M. Regarding current trading prices, NUMIF is priced at $0.01, while KJFI trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas KJFI's P/E ratio is -0.06. In terms of profitability, NUMIF's ROE is +11.51%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, NUMIF is more volatile compared to KJFI. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check KJFI's competition here
NUMIF vs GRST Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, GRST has a market cap of 1.5M. Regarding current trading prices, NUMIF is priced at $0.01, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas GRST's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to GRST's ROE of +0.17%. Regarding short-term risk, NUMIF is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GRST's competition here
NUMIF vs SMAS Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, NUMIF is priced at $0.01, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas SMAS's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to SMAS's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check SMAS's competition here
NUMIF vs MDGP Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, NUMIF is priced at $0.01, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MDGP's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, NUMIF is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MDGP's competition here
NUMIF vs MAHN Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MAHN has a market cap of 1.2M. Regarding current trading prices, NUMIF is priced at $0.01, while MAHN trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MAHN's P/E ratio is 50.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to MAHN's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to MAHN. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check MAHN's competition here
NUMIF vs NOVC Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, NUMIF is priced at $0.01, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NOVC's P/E ratio is -0.20. In terms of profitability, NUMIF's ROE is +11.51%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, NUMIF is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NOVC's competition here
NUMIF vs DPAT Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, DPAT has a market cap of 1.1M. Regarding current trading prices, NUMIF is priced at $0.01, while DPAT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas DPAT's P/E ratio is -2.25. In terms of profitability, NUMIF's ROE is +11.51%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, NUMIF is more volatile compared to DPAT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check DPAT's competition here
NUMIF vs PHMB Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, NUMIF is priced at $0.01, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas PHMB's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to PHMB's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check PHMB's competition here
NUMIF vs GNOW Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, NUMIF is priced at $0.01, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas GNOW's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to GNOW's ROE of -12.49%. Regarding short-term risk, NUMIF is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check GNOW's competition here
NUMIF vs JRSS Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, JRSS has a market cap of 837.5K. Regarding current trading prices, NUMIF is priced at $0.01, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas JRSS's P/E ratio is -0.10. In terms of profitability, NUMIF's ROE is +11.51%, compared to JRSS's ROE of +0.89%. Regarding short-term risk, NUMIF is more volatile compared to JRSS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JRSS's competition here
NUMIF vs MSITF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, NUMIF is priced at $0.01, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MSITF's P/E ratio is -0.10. In terms of profitability, NUMIF's ROE is +11.51%, compared to MSITF's ROE of N/A. Regarding short-term risk, NUMIF is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check MSITF's competition here
NUMIF vs ARPC Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, NUMIF is priced at $0.01, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ARPC's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, NUMIF is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ARPC's competition here
NUMIF vs NXGT Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NXGT has a market cap of 292.2K. Regarding current trading prices, NUMIF is priced at $0.01, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NXGT's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to NXGT's ROE of +0.04%. Regarding short-term risk, NUMIF is more volatile compared to NXGT. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NXGT's competition here
NUMIF vs BNYN Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, NUMIF is priced at $0.01, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BNYN's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, NUMIF is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check BNYN's competition here
NUMIF vs SETO Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, SETO has a market cap of 234.5K. Regarding current trading prices, NUMIF is priced at $0.01, while SETO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas SETO's P/E ratio is -1.88. In terms of profitability, NUMIF's ROE is +11.51%, compared to SETO's ROE of -123.80%. Regarding short-term risk, NUMIF is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check SETO's competition here
NUMIF vs FCHS Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, FCHS has a market cap of 131.8K. Regarding current trading prices, NUMIF is priced at $0.01, while FCHS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas FCHS's P/E ratio is -0.04. In terms of profitability, NUMIF's ROE is +11.51%, compared to FCHS's ROE of +0.20%. Regarding short-term risk, NUMIF is more volatile compared to FCHS. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check FCHS's competition here
NUMIF vs TPIA Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, NUMIF is priced at $0.01, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas TPIA's P/E ratio is -0.15. In terms of profitability, NUMIF's ROE is +11.51%, compared to TPIA's ROE of +0.55%. Regarding short-term risk, NUMIF is more volatile compared to TPIA. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check TPIA's competition here
NUMIF vs AMBD Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, NUMIF is priced at $0.01, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas AMBD's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, NUMIF is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check AMBD's competition here
NUMIF vs JNHMF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, JNHMF has a market cap of 69.7K. Regarding current trading prices, NUMIF is priced at $0.01, while JNHMF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas JNHMF's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to JNHMF's ROE of -3.60%. Regarding short-term risk, NUMIF is more volatile compared to JNHMF. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check JNHMF's competition here
NUMIF vs NMHLY Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, NUMIF is priced at $0.01, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, NUMIF's ROE is +11.51%, compared to NMHLY's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check NMHLY's competition here
NUMIF vs CLRD Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, CLRD has a market cap of 28.8K. Regarding current trading prices, NUMIF is priced at $0.01, while CLRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas CLRD's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, NUMIF is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check CLRD's competition here
NUMIF vs MSGP Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, MSGP has a market cap of 26K. Regarding current trading prices, NUMIF is priced at $0.01, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas MSGP's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, NUMIF is less volatile compared to MSGP. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check MSGP's competition here
NUMIF vs HSMD Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, HSMD has a market cap of 18.4K. Regarding current trading prices, NUMIF is priced at $0.01, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas HSMD's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, NUMIF is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check HSMD's competition here
NUMIF vs SCAL Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, NUMIF is priced at $0.01, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas SCAL's P/E ratio is 0.04. In terms of profitability, NUMIF's ROE is +11.51%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, NUMIF is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check SCAL's competition here
NUMIF vs CEVE Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, CEVE has a market cap of 17.1K. Regarding current trading prices, NUMIF is priced at $0.01, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas CEVE's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, NUMIF is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CEVE's competition here
NUMIF vs PRMD Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, PRMD has a market cap of 12.9K. Regarding current trading prices, NUMIF is priced at $0.01, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas PRMD's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, NUMIF is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check PRMD's competition here
NUMIF vs GENN Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, NUMIF is priced at $0.01, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas GENN's P/E ratio is -0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to GENN's ROE of +0.07%. Regarding short-term risk, NUMIF is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check GENN's competition here
NUMIF vs CHCR Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, NUMIF is priced at $0.01, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas CHCR's P/E ratio is -0.00. In terms of profitability, NUMIF's ROE is +11.51%, compared to CHCR's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check CHCR's competition here
NUMIF vs ACGI Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, NUMIF is priced at $0.01, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ACGI's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, NUMIF is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check ACGI's competition here
NUMIF vs WEQL Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, WEQL has a market cap of 7.2K. Regarding current trading prices, NUMIF is priced at $0.01, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas WEQL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, NUMIF is less volatile compared to WEQL. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check WEQL's competition here
NUMIF vs PAOG Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, PAOG has a market cap of 5K. Regarding current trading prices, NUMIF is priced at $0.01, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas PAOG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to PAOG's ROE of -0.20%. Regarding short-term risk, NUMIF is more volatile compared to PAOG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check PAOG's competition here
NUMIF vs SLHGF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, SLHGF has a market cap of 4K. Regarding current trading prices, NUMIF is priced at $0.01, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas SLHGF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to SLHGF's ROE of -0.42%. Regarding short-term risk, NUMIF is less volatile compared to SLHGF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check SLHGF's competition here
NUMIF vs SLHPF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, NUMIF is priced at $0.01, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas SLHPF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to SLHPF's ROE of -0.42%. Regarding short-term risk, NUMIF is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check SLHPF's competition here
NUMIF vs ERUC Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, ERUC has a market cap of 3.9K. Regarding current trading prices, NUMIF is priced at $0.01, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas ERUC's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to ERUC's ROE of N/A. Regarding short-term risk, NUMIF is more volatile compared to ERUC. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check ERUC's competition here
NUMIF vs BBAL Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, NUMIF is priced at $0.01, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BBAL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, NUMIF is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BBAL's competition here
NUMIF vs DRWN Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, DRWN has a market cap of 2.4K. Regarding current trading prices, NUMIF is priced at $0.01, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas DRWN's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, NUMIF is more volatile compared to DRWN. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check DRWN's competition here
NUMIF vs NMMCF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, NUMIF is priced at $0.01, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas NMMCF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to NMMCF's ROE of +0.21%. Regarding short-term risk, NUMIF is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check NMMCF's competition here
NUMIF vs PPRG Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, NUMIF is priced at $0.01, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas PPRG's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, NUMIF is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check PPRG's competition here
NUMIF vs KONEF Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, KONEF has a market cap of 1.6K. Regarding current trading prices, NUMIF is priced at $0.01, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas KONEF's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, NUMIF is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for NUMIF.Check KONEF's competition here
NUMIF vs OHAQ Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, NUMIF is priced at $0.01, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, NUMIF's ROE is +11.51%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, NUMIF is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check OHAQ's competition here
NUMIF vs BNKL Comparison April 2026
NUMIF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUMIF stands at 2.9M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, NUMIF is priced at $0.01, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUMIF currently has a P/E ratio of -0.30, whereas BNKL's P/E ratio is N/A. In terms of profitability, NUMIF's ROE is +11.51%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, NUMIF is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for NUMIF.Check BNKL's competition here